Preparation of extracellular domain 3 of human VEGF receptor‐2 and the monitoring of its real‐time binding to VEGF by biosensors
暂无分享,去创建一个
Peng Cao | Min Wang | Wei Chen | Haixin Li | P. Cao | Haixin Li | Juan Zhang | Juan Zhang | Wei Chen | Min Wang
[1] Zhen-ping Zhu,et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. , 2006, Biochemical and biophysical research communications.
[2] B. Kou,et al. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. , 2004, Experimental and molecular pathology.
[3] P. Bohlen,et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy , 2002, International journal of cancer.
[4] M. Váradi,et al. Modification of the surface of integrated optical wave-guide sensors for immunosensor applications , 2001, Fresenius' journal of analytical chemistry.
[5] P. R. V. Tassel,et al. Kinetic Regimes of Protein Adsorption , 2001 .
[6] P. Gerwins,et al. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. , 2000, Critical reviews in oncology/hematology.
[7] P. Bohlen,et al. Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies* , 2000, The Journal of Biological Chemistry.
[8] P E Thorpe,et al. Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. , 1998, Biochemical and biophysical research communications.
[9] Ramsden,et al. A Particle-Level Model of Irreversible Protein Adsorption with a Postadsorption Transition. , 1998, Journal of colloid and interface science.
[10] K. Alfthan,et al. Surface plasmon resonance biosensors as a tool in antibody engineering. , 1998, Biosensors & bioelectronics.
[11] K.,et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] D. Hicklin,et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.
[13] B. Li,et al. Requirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor* , 1998, The Journal of Biological Chemistry.
[14] J. Ramsden,et al. Kinetics of the interaction between DNA and the type IC restriction enzyme EcoR124II. , 1996, Biochemistry.
[15] D. Dimitrov,et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.
[16] R. Karlsson,et al. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.
[17] A. Bikfalvi,et al. Tumor angiogenesis , 2020, Advances in cancer research.
[18] Liu Yu. Pichia Expression of Recombined Human VEGF_(165) and Activity Determination , 2004 .
[19] M. Clauss. Molecular Biology of the VEGF and the VEGF Receptor Family , 2000, Seminars in thrombosis and hemostasis.
[20] M. Dewhirst,et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.